ReviewEuropean journal of nuclear medicine and molecular imaging2010
Angiogenesis imaging with vascular-constrained particles: the why and how.
Review in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A Glimpse into Dendrimers Integration in Cancer Imaging and Theranostics.International journal of molecular sciences · 2023Review
- A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome.International journal of general medicine · 2022Article
- Tumor angiogenesis targeting and imaging using gold nanoparticle probe with directly conjugated cyclic NGR.RSC advances · 2018Article
- Applications of nanoparticles for diagnosis and therapy of cancer.The British journal of radiology · 2015Review
- High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties.ACS nano · 2014Article
- Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Scientifica · 2014Review
- Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.Theranostics · 2014Article
- Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging.Neoplasia (New York, N.Y.) · 2012Article
- Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonography.World journal of radiology · 2012Article
- Manganese-based MRI contrast agents: past, present and future.Tetrahedron · 2011Article
- Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Nature reviews. Drug discovery · 2011Review
- Estimation of intra-operator variability in perfusion parameter measurements using DCE-US.World journal of radiology · 2011Article
- Imaging of angiogenesis: from morphology to molecules and from bench to bedside.European journal of nuclear medicine and molecular imaging · 2010Article
- Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is a keystone in the treatment of cancer and potentially many other diseases. In cancer, first-generation antiangiogenic therapeutic approaches have demonstrated survival benefit in subsets of patients, but their high cost and notable adverse side effect risk have fueled alternative development efforts to personalize patient selection and reduce off-target effects. In parallel, rapid advances in cost-effective genomic profiling and sensitive early detection of high-risk biomarkers for cancer, atherosclerosis, and other angiogenesis-related pathologies will challenge the medical imaging community to identify, characterize, and risk stratify patients early in the natural history of these disease processes. Conventional diagnostic imaging techniques were not intended for such sensitive and specific detection, which has led to the emergence of novel noninvasive biomedical imaging approaches. The overall intent of molecular imaging is to achieve greater quantitative characterization of pathologies based on microanatomical, biochemical, or functional assessments; in many approaches, the capacity to deliver effective therapy, e.g., antiangiogenic therapy, can be combined. Agents with both diagnostic and therapy attributes have acquired the moniker "theranostics." This review will explore biomedical imaging options being pursued to better segment and treat patients with angiogenesis-influenced disease using vascular-constrained contrast platform technologies.
Indexed as
Identifiers
20617434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.